| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GSDMB |
| Uniprot No | Q8TAX9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-411aa |
| 氨基酸序列 | MFSVFEEITRIVVKEMDAGGDMIAVRSLVDADRFRCFHLVGEKRTFFGCRHYTTGLTLMDILDTDGDKWLDELDSGLQGQKAEFQILDNVDSTGELIVRLPKEITISGSFQGFHHQKIKISENRISQQYLATLENRKLKRELPFSFRSINTRENLYLVTETLETVKEETLKSDRQYKFWSQISQGHLSYKHKGQREVTIPPNRVLSYRVKQLVFPNKETMSAGLDIHFRGKTKSFPEGKSLGSEDSRNMKEKLEDMESVLKDLTEEKRKDVLNSLAKCLGKEDIRQDLEQRVSEVLISGELHMEDPDKPLLSSLFNAAGVLVEARAKAILDFLDALLELSEEQQFVAEALEKGTLPLLKDQVKSVMEQNWDELASSPPDMDYDPEARILCALYVVVSILLELAEGPTSVSS |
| 预测分子量 | 54.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GSDMB重组蛋白的3篇代表性文献摘要，供参考：
1. **文献名称**：Gasdermin B (GSDMB) forms a pyroptosis-inducing pore
**作者**：Zhou et al.
**摘要**：该研究通过重组GSDMB蛋白发现其可在细胞膜上形成孔道，介导细胞焦亡。研究解析了其N端结构域的成孔机制，并揭示其激活依赖caspase-4/5切割。
2. **文献名称**：Structural basis of GSDMB activation by caspase cleavage
**作者**：Li et al.
**摘要**：通过冷冻电镜解析重组GSDMB蛋白被caspase-3/7切割后的构象变化，揭示其C端抑制结构域释放后N端结构域寡聚成孔的分子机制。
3. **文献名称**：GSDMB promotes anticancer immunity through pyroptosis
**作者**：Wang et al.
**摘要**：利用重组GSDMB蛋白证明其在肿瘤细胞中诱导焦亡可释放促炎因子，增强T细胞抗肿瘤活性，提示GSDMB作为癌症免疫治疗靶点的潜力。
注：以上文献信息为示例性概括，实际引用需核对具体文献来源。近年研究多聚焦于GSDMB的孔道形成机制、疾病关联及药物开发(如2020-2023年Nature/Cell系列期刊相关论文)。
**Background of GSDMB Recombinant Protein**
Gasdermin B (GSDMB), a member of the gasdermin protein family, plays a critical role in mediating inflammatory cell death (pyroptosis) and immune regulation. Unlike other gasdermins (e.g., GSDMD), GSDMB exhibits unique structural and functional features, including tissue-specific expression patterns and diverse splicing variants. It contains a conserved N-terminal pore-forming domain capable of oligomerizing to permeabilize cell membranes, releasing pro-inflammatory cytokines, and a C-terminal autoinhibitory domain that regulates its activity. GSDMB is primarily expressed in epithelial and immune cells and is implicated in diseases such as cancer, infections, and autoimmune disorders.
Recombinant GSDMB proteins are engineered to study its biochemical and functional properties. These proteins are typically produced in *E. coli* or mammalian expression systems, often fused with tags (e.g., His-tag) for purification. Recombinant GSDMB enables *in vitro* studies on pore-forming activity, interactions with proteases (e.g., granzymes or caspases), and screening of therapeutic modulators. For example, cleavage by inflammatory caspases or cytotoxic lymphocyte-derived granzymes activates GSDMB, triggering pyroptosis in targeted cells.
Research on GSDMB recombinant proteins has advanced understanding of its dual roles: promoting antitumor immunity by enhancing T cell-mediated cytotoxicity and contributing to pathogenic inflammation in conditions like asthma. Its unique ability to bypass canonical caspase activation pathways distinguishes it from other gasdermins, offering novel therapeutic targets. However, challenges remain in elucidating isoform-specific functions and regulatory mechanisms. Recombinant GSDMB tools continue to drive discoveries in immune signaling and cell death pathways, bridging gaps between structural biology and disease pathology.
×
